Lauren L Jantzie1, Robert H Miller2, Shenandoah Robinson1. 1. Departments of Neurosurgery and Neurology, F.M. Kirby Center for Neurobiology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 2. Department of Neurosciences, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Abstract
BACKGROUND: Brain injury from preterm birth causes white matter injury (WMI), and it leads to chronic neurological deficits including cerebral palsy, epilepsy, cognitive, and behavioral delay. Immature O4+ oligodendrocytes are particularly vulnerable to WMI. Understanding how the developing brain recovers after injury is essential to finding more effective therapeutic strategies. Erythropoietin (EPO) promotes neuronal recovery after injury; however, its role in enhancing oligodendroglial lineage recovery is unclear. Previously, we found that recombinant EPO (rEPO) treatment enhances myelin basic protein (MBP) expression and functional recovery in adult rats after prenatal transient systemic hypoxia-ischemia (TSHI). We hypothesized that after injury, rEPO would enhance oligodendroglial lineage cell genesis, survival, maturation, and myelination. METHODS: In vitro assays were used to define how rEPO contributes to specific stages of oligodendrocyte development and recovery after TSHI. RESULTS: After prenatal TSHI injury, rEPO promotes genesis of oligodendrocyte progenitors from oligodendrospheres, survival of oligodendrocyte precursor cells (OPCs) and O4+ immature oligodendrocytes, O4+ cell process extension, and MBP expression. rEPO did not alter OPC proliferation. CONCLUSION: Together, these studies demonstrate that EPO signaling promotes critical stages of oligodendroglial lineage development and recovery after prenatal TSHI injury. EPO treatment may be beneficial to preterm and other infant patient populations with developmental brain injury hallmarked by WMI.
BACKGROUND:Brain injury from preterm birth causes white matter injury (WMI), and it leads to chronic neurological deficits including cerebral palsy, epilepsy, cognitive, and behavioral delay. Immature O4+ oligodendrocytes are particularly vulnerable to WMI. Understanding how the developing brain recovers after injury is essential to finding more effective therapeutic strategies. Erythropoietin (EPO) promotes neuronal recovery after injury; however, its role in enhancing oligodendroglial lineage recovery is unclear. Previously, we found that recombinant EPO (rEPO) treatment enhances myelin basic protein (MBP) expression and functional recovery in adult rats after prenatal transient systemic hypoxia-ischemia (TSHI). We hypothesized that after injury, rEPO would enhance oligodendroglial lineage cell genesis, survival, maturation, and myelination. METHODS: In vitro assays were used to define how rEPO contributes to specific stages of oligodendrocyte development and recovery after TSHI. RESULTS: After prenatal TSHI injury, rEPO promotes genesis of oligodendrocyte progenitors from oligodendrospheres, survival of oligodendrocyte precursor cells (OPCs) and O4+ immature oligodendrocytes, O4+ cell process extension, and MBP expression. rEPO did not alter OPC proliferation. CONCLUSION: Together, these studies demonstrate that EPO signaling promotes critical stages of oligodendroglial lineage development and recovery after prenatal TSHI injury. EPO treatment may be beneficial to preterm and other infantpatient populations with developmental brain injury hallmarked by WMI.
Authors: Masanori Iwai; R Anne Stetler; Juan Xing; Xiaoming Hu; Yanqin Gao; Wenting Zhang; Jun Chen; Guodong Cao Journal: Stroke Date: 2010-04-01 Impact factor: 7.914
Authors: Yun Kyung Cho; Gunha Kim; Serah Park; Ju Hee Sim; You Jin Won; Chang Ho Hwang; Jong Yoon Yoo; Hea Nam Hong Journal: Biochem Biophys Res Commun Date: 2011-12-16 Impact factor: 3.575
Authors: Xiyong Fan; Cobi J Heijnen; Michael A van der KOOIJ; Floris Groenendaal; Frank van Bel Journal: Pediatr Res Date: 2011-01 Impact factor: 3.756
Authors: Shenandoah Robinson; Kasia Petelenz; Qing Li; Mark L Cohen; Anne Dechant; Nanor Tabrizi; Marik Bucek; David Lust; Robert H Miller Journal: Neurobiol Dis Date: 2005-04 Impact factor: 5.996
Authors: Sandra E Juul; Ronald J McPherson; Larry A Bauer; Kelly J Ledbetter; Christine A Gleason; Dennis E Mayock Journal: Pediatrics Date: 2008-08 Impact factor: 7.124
Authors: Lian Li; Quan Jiang; Guangliang Ding; Li Zhang; Zheng Gang Zhang; Qingjiang Li; Swayamprava Panda; Alissa Kapke; Mei Lu; James R Ewing; Michael Chopp Journal: Stroke Date: 2009-01-15 Impact factor: 7.914
Authors: Sandra E Juul; Bryan A Comstock; Patrick J Heagerty; Dennis E Mayock; Amy M Goodman; Stephanie Hauge; Fernando Gonzalez; Yvonne W Wu Journal: Neonatology Date: 2018-03-07 Impact factor: 4.035
Authors: Robin K Ohls; Daniel C Cannon; John Phillips; Arvind Caprihan; Shrena Patel; Sarah Winter; Michael Steffen; Ronald A Yeo; Richard Campbell; Susan Wiedmeier; Shawna Baker; Sean Gonzales; Jean Lowe Journal: Pediatrics Date: 2016-02-15 Impact factor: 7.124